samedan logo
 
 
 
spacer
home > pmps > summer 2003 > the clock ticks for industry compliance on new blister pack standard
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

the Clock Ticks for Industry Compliance on New Blister Pack Standard

Before the end of this year, government legislation will require certain medicines consumed in the UK to comply with a new child-resistant standard. To manufacturers, the implications of this are considerable, not least the potential impact on their production line throughput. However becoming compliant need not be such a headache.

BS8404 is the new child-resistant (CR) standard for blister and strip packs, currently being fast-tracked to legislation by the UK Government and the Medicines and Healthcare Products Regulatory Agency (MHRA). It is expected to become effective as of October 2003, when packs containing aspirin, paracetamol and iron will be required to comply with the new standard. In market terms, this amounts to a total of around 800 million blister packs a year.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jonathan Bobbett, Managing Director of Pill protect™

Jonathan Bobbett is the Owner and Managing Director of Pill protect™ which is part of Three Point Blue Ltd which Jonathan has run for over 15 years.

In addition to Pill protect™, Three Point Blue Ltd offers a range of established creative communication services including branding, graphic design, print management and online system development.

spacer
Jonathan Bobbett
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement